Exact Sciences Corp
EXAS53.520USD
-0.490-0.91%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
10.09BValor de mercado
PerdaP/L TTM
Mais detalhes de Exact Sciences Corp Empresa
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Informações da empresa
Código da empresaEXAS
Nome da EmpresaExact Sciences Corp
Data de listagemJan 30, 2001
Fundado em1995
CEOMr. Kevin T. Conroy
Número de funcionários6900
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
Endereço5505 Endeavor Lane
CidadeMADISON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal53719
Telefone16082845700
Sitehttps://www.exactsciences.com/
Código da empresaEXAS
Data de listagemJan 30, 2001
Fundado em1995
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
70.57K
--
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
28.91K
--
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
23.50K
--
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Ms. Leslie L. Trigg
Ms. Leslie L. Trigg
Independent Director
Independent Director
9.50K
--
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
6.39K
--
Mr. Michael J. (Mike) Barber, M.D.
Mr. Michael J. (Mike) Barber, M.D.
Independent Director
Independent Director
5.94K
--
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.14M
-20.54%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
70.57K
--
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
28.91K
--
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
23.50K
--
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
23.26K
+0.94%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
13.84K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Commercial
1.31B
47.44%
Medicare Parts B & C
964.10M
34.95%
Other
296.74M
10.76%
International
189.09M
6.85%
COVID 19 testing
0.00
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States (Country)
2.57B
93.15%
Outside of united states
189.09M
6.85%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Commercial
1.31B
47.44%
Medicare Parts B & C
964.10M
34.95%
Other
296.74M
10.76%
International
189.09M
6.85%
COVID 19 testing
0.00
0.00%
Distribuição de ações
Atualizado em: ter, 20 de mai
Atualizado em: ter, 20 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.80%
Capital World Investors
9.45%
The Vanguard Group, Inc.
9.31%
Wellington Management Company, LLP
6.63%
BlackRock Institutional Trust Company, N.A.
4.07%
Other
57.74%
Tipos de investidores
Investidores
Proporção
Investment Advisor
51.79%
Investment Advisor/Hedge Fund
36.26%
Hedge Fund
4.35%
Research Firm
2.51%
Bank and Trust
1.35%
Pension Fund
1.13%
Individual Investor
0.89%
Sovereign Wealth Fund
0.56%
Private Equity
0.36%
Other
0.81%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1394
200.40M
106.36%
-205.96K
2024Q4
1411
200.72M
108.09%
-225.66K
2024Q3
1375
190.82M
103.28%
-5.17M
2024Q2
1358
185.25M
100.40%
+6.59M
2024Q1
1347
168.41M
92.78%
-6.10M
2023Q4
1356
165.31M
91.41%
-11.01M
2023Q3
1337
167.70M
92.83%
-6.22M
2023Q2
1354
166.38M
92.24%
-10.65M
2023Q1
1343
167.01M
92.90%
-8.56M
2022Q4
1337
163.71M
92.15%
-9.28M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
18.85M
10.15%
-712.35K
-3.64%
Dec 31, 2024
Capital World Investors
17.54M
9.44%
+1.70M
+10.71%
Dec 31, 2024
The Vanguard Group, Inc.
16.95M
9.12%
-741.47K
-4.19%
Dec 31, 2024
Wellington Management Company, LLP
12.06M
6.49%
-2.27M
-15.86%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.66M
4.13%
+245.10K
+3.30%
Dec 31, 2024
State Street Global Advisors (US)
6.23M
3.36%
-447.40K
-6.70%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
3.03%
+2.48M
+78.79%
Dec 31, 2024
Fidelity Institutional Asset Management
1.90M
1.02%
-182.61K
-8.76%
Dec 31, 2024
Mackenzie Investments
2.92M
1.57%
+1.51M
+107.71%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.12M
1.68%
+16.83K
+0.54%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
First Trust NYSE Arca Biotechnology Index Fund
3.88%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.46%
Invesco Biotechnology & Genome ETF
3.25%
SPDR S&P Biotech ETF
2.95%
Nuveen ESG Mid-Cap Growth ETF
2.6%
First Trust Indxx Medical Devices ETF
2.39%
iShares Health Innovation Active ETF
2.07%
Franklin Genomic Advancements ETF
2.04%
ROBO Global Healthcare Technology & Innovation ETF
1.95%
Direxion Daily S&P Biotech Bull 3X Shares
1.93%
Ver Mais
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.88%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção3.46%
Invesco Biotechnology & Genome ETF
Proporção3.25%
SPDR S&P Biotech ETF
Proporção2.95%
Nuveen ESG Mid-Cap Growth ETF
Proporção2.6%
First Trust Indxx Medical Devices ETF
Proporção2.39%
iShares Health Innovation Active ETF
Proporção2.07%
Franklin Genomic Advancements ETF
Proporção2.04%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.95%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.93%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
